Research programme: anti-microbial therapeutics - Assembly Biosciences

Drug Profile

Research programme: anti-microbial therapeutics - Assembly Biosciences

Alternative Names: AB M102; AB M103; ABI M201; ABI M301; ABI-M101; ABM-101; Gemicel based therapeutics - Ventrus Biosciences; Gemicel based therapeutics -Assembly Biosciences; Microbiome therapeutics - Assembly Biosciences

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Assembly Biosciences
  • Class Bacteria; Proteins; Small molecules; Viruses
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections
  • Research Crohn's disease; Irritable bowel syndrome; Ulcerative colitis

Most Recent Events

  • 21 Feb 2017 Assembly Biosciences receives early termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for licensing agreement with Allergan
  • 09 Jan 2017 ABI M201, ABI M301 and two compounds for Ulcerative colitis, Crohn's disease and Irritable bowel syndrome licensed to Allergan in World
  • 09 Jan 2017 Early research in Crohn's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top